The presence of circulating free tumour DNA for the mutations BRAF, K-ras, N-ras, and PIK3CA mutations has been used to identify patients with MRD and also as a marker for the resistance to EGFR therapy, such as cetuximab or panitumumab [20]. Here, NRAS is linked to neoplasm.